MCID: URM002
MIFTS: 50

Uremia

Categories: Nephrological diseases

Aliases & Classifications for Uremia

MalaCards integrated aliases for Uremia:

Name: Uremia 12 75 55 44 15 17 72
Uremia of Renal Origin 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4676
MeSH 44 D014511
SNOMED-CT 68 44730006
ICD10 33 N19
UMLS 72 C0041948

Summaries for Uremia

MalaCards based summary : Uremia, also known as uremia of renal origin, is related to deficiency anemia and hyperphosphatemia. An important gene associated with Uremia is EPO (Erythropoietin), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Ca, cAMP and Lipid Signaling. The drugs Fexofenadine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and liver, and related phenotypes are cellular and cardiovascular system

Wikipedia : 75 Uremia is the condition of having high levels of urea in the blood. Urea is one of the primary... more...

Related Diseases for Uremia

Diseases related to Uremia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 480)
# Related Disease Score Top Affiliating Genes
1 deficiency anemia 31.2 EPO CRP ALB
2 hyperphosphatemia 31.2 VDR PTH CASR
3 hyperparathyroidism 31.1 VDR TNFRSF11B PTH EPO CASR
4 end stage renal failure 31.1 PTH LEP EPO CRP ALB
5 uremic neuropathy 30.9 PTH EPO B2M
6 osteomalacia 30.9 VDR PTH CASR
7 osteitis fibrosa 30.9 PTH CASR B2M
8 peritonitis 30.8 CRP B2M ALB
9 renal osteodystrophy 30.7 VDR TNFRSF11B PTH CASR
10 diffuse glomerulonephritis 30.7 B2M ALB
11 arteriosclerosis 30.6 SPP1 INS CRP
12 multiple endocrine neoplasia, type i 30.4 PTH INS CASR
13 acquired immunodeficiency syndrome 30.4 EPO B2M ALB
14 hypertriglyceridemia, familial 30.4 LPL INS APOC3
15 analbuminemia 30.4 EPO CRP ALB
16 parathyroid adenoma 30.4 VDR PTH CASR
17 pulmonary embolism 30.4 VWF CRP ALB
18 arthropathy 30.4 TNFRSF11B CRP B2M
19 primary hyperparathyroidism 30.3 VDR PTH CASR ALB
20 bone resorption disease 30.3 VDR TNFRSF11B SPP1 PTH
21 hyperglycemia 30.3 LEP INS ALB
22 insulin-like growth factor i 30.2 LEP INS GHR
23 sleep apnea 30.2 LEP INS CRP
24 nephrocalcinosis 30.2 SPP1 PTH CASR ALB
25 nephrolithiasis, calcium oxalate 30.1 VDR SPP1 CASR
26 bone disease 30.1 VDR TNFRSF11B SPP1 PTH CASR B2M
27 peripheral vascular disease 30.1 VWF CRP ALB
28 nutritional deficiency disease 30.1 LEP EPO CRP ALB
29 sleep disorder 30.1 LEP INS CRP
30 calciphylaxis 29.9 VDR PTH EPO CASR ALB
31 arteries, anomalies of 29.9 VWF LEP INS CRP ALB
32 pancreatitis 29.8 LPL CRP CASR
33 myeloma, multiple 29.6 TNFRSF11B EPO CRP B2M ALB
34 cerebrovascular disease 29.6 VWF INS CRP
35 glucose intolerance 29.4 RETN LPL LEP INS CRP
36 proteasome-associated autoinflammatory syndrome 1 29.2 RETN NOS2 INS CRP ALB
37 heart disease 29.1 VWF LPL INS CRP APOC3 ALB
38 gestational diabetes 29.1 RETN LEP INS
39 diabetes mellitus 28.5 RETN LPL LEP INS EPO CRP
40 lipid metabolism disorder 28.4 RETN LPL LEP INS CRP APOC3
41 kidney disease 28.4 VDR TNFRSF11B SPP1 PTH INS EPO
42 coronary heart disease 1 28.4 RETN LPL INS CRP APOC3
43 myocardial infarction 28.1 VWF RETN INS CRP APOC3 ALB
44 vascular disease 27.9 VWF TNFRSF11B RETN NOS2 LPL INS
45 hypertension, essential 27.6 VWF RETN NOS2 LPL LEP INS
46 body mass index quantitative trait locus 11 26.4 RETN LPL LEP INS GHR CRP
47 diabetes mellitus, noninsulin-dependent 26.2 VWF RETN LPL LEP INS CRP
48 microvascular complications of diabetes 3 11.6
49 nephronophthisis 1 11.4
50 malignant otitis externa 10.7 INS CRP

Graphical network of the top 20 diseases related to Uremia:



Diseases related to Uremia

Symptoms & Phenotypes for Uremia

MGI Mouse Phenotypes related to Uremia:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 ALB B2M CASR EPO GHR INS
2 cardiovascular system MP:0005385 10.36 B2M CRP EPO GHR INS LEP
3 homeostasis/metabolism MP:0005376 10.36 AHSG ALB B2M CASR CRP EPO
4 immune system MP:0005387 10.28 B2M CASR CRP EPO GHR INS
5 growth/size/body region MP:0005378 10.27 AHSG B2M CASR GHR INS LEP
6 hematopoietic system MP:0005397 10.26 B2M CASR EPO GHR INS LEP
7 endocrine/exocrine gland MP:0005379 10.16 ALB B2M CASR GHR INS LEP
8 digestive/alimentary MP:0005381 10.13 ALB B2M CASR INS LEP NOS2
9 integument MP:0010771 10.1 B2M CASR EPO GHR INS LEP
10 mortality/aging MP:0010768 10.1 ALB B2M CASR EPO GHR INS
11 adipose tissue MP:0005375 10.03 GHR INS LEP LPL NOS2 RETN
12 liver/biliary system MP:0005370 10.02 ALB B2M EPO GHR INS LEP
13 limbs/digits/tail MP:0005371 9.91 AHSG EPO GHR LEP PTH TNFRSF11B
14 muscle MP:0005369 9.9 AHSG ALB CASR EPO GHR INS
15 renal/urinary system MP:0005367 9.56 ALB CASR GHR INS LEP NOS2
16 skeleton MP:0005390 9.36 AHSG CASR EPO GHR INS LEP

Drugs & Therapeutics for Uremia

Drugs for Uremia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
6
Hydralazine Approved Phase 4 86-54-4 3637
7
Enalaprilat Approved Phase 4 76420-72-9 6917719
8
Cefazolin Approved Phase 4 25953-19-9 656510 33255
9
leucovorin Approved Phase 4 58-05-9 143 6006
10
Metformin Approved Phase 4 657-24-9 4091 14219
11
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
12
Liraglutide Approved Phase 4 204656-20-2 44147092
13
carbamide peroxide Approved Phase 4 124-43-6
14
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
15
tannic acid Approved Phase 4 1401-55-4
16
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
17
Pamidronate Approved Phase 4 40391-99-9 4674
18
Pantoprazole Approved Phase 4 102625-70-7 4679
19
Amlodipine Approved Phase 4 88150-42-9 2162
20
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
21
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
22
Zinc Approved, Investigational Phase 4 7440-66-6 32051
23
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
24
Losartan Approved Phase 4 114798-26-4 3961
25
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
27
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
28
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
29 Psychotropic Drugs Phase 4
30 HIV Protease Inhibitors Phase 4
31
protease inhibitors Phase 4
32 Tranquilizing Agents Phase 4
33 Anti-Anxiety Agents Phase 4
34 Central Nervous System Depressants Phase 4
35 Analgesics Phase 4
36 Anti-Allergic Agents Phase 4
37
Histamine Phosphate Phase 4 51-74-1 65513
38 Histamine H1 Antagonists Phase 4
39 Histamine Antagonists Phase 4
40 Anticonvulsants Phase 4
41 Histamine H1 Antagonists, Non-Sedating Phase 4
42 Adrenergic beta-Antagonists Phase 4
43 Dialysis Solutions Phase 4
44 Pharmaceutical Solutions Phase 4
45 Micronutrients Phase 4
46 Trace Elements Phase 4
47 Vitamins Phase 4
48 Vitamin B9 Phase 4
49 Vitamin B Complex Phase 4
50 Folate Phase 4

Interventional clinical trials:

(show top 50) (show all 128)
# Name Status NCT ID Phase Drugs
1 The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis Unknown status NCT01076426 Phase 4 Pro-biotics
2 A Multicenter, Double-blind, Randomized, Placebo and Active-controlled Study of Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
3 The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients Unknown status NCT01041963 Phase 4 Enalapril;Enalapril plus Losartan;Placebo
4 The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients Unknown status NCT01305850 Phase 4 placebo;Aliskiren;Aliskiren plus Losartan;Enalapril plus Losartan
5 Gut-kidney Axis: Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids to Restore Physiological Intestinal Mibrobiota in Chronic Kidney Disease Unknown status NCT02302287 Phase 4
6 The Impact of Early Feeding Following Ligation of the Acute Bleeding Varices Unknown status NCT01287702 Phase 4
7 Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial Unknown status NCT02534961 Phase 4 Cefazolin
8 Randomized Clinical Trial of Folate Therapy/Placebo for Reduction of Homocysteine Serum Levels in Uremic Patients and Influence on Cardiovascular Mortality Completed NCT00317005 Phase 4 folate treatment
9 PHASE 4 STUDY OT THE EFFECT OF GLUCOSE ADDED TO THE DIALYSIS FLUID ON BLOOD PRESSURE, BLOOD GLUCOSE AND QUALITY OF LIFE IN HEMODIALYSIS PATIENTS. Completed NCT00278057 Phase 4 dialysisis with and without glucose in the dialysis
10 Phase 4 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease Completed NCT00513630 Phase 4 Glipizide;Metformin
11 Effect of Heat Disinfection of HD Water Treatment System on Cardiovascular Events and Outcome in Hemodialysis Patients Completed NCT01138280 Phase 4
12 Safety and Effect of Liraglutide in Patients With Type 2 Diabetes and Severe Renal Insufficiency Completed NCT01394341 Phase 4 Liraglutide
13 An Open Label, Multi-Center Study of the Effect of Paricalcitol on Markers of Inflammation in Patients With Stage 5 Chronic Kidney Disease on Hemodialysis. Completed NCT00294866 Phase 4 Paricalcitol
14 The Rates of Complete Symptom Relief,Prevetion of Symptom Relapse and Maintenance of Esophagitis Healing for 4-week Versus 8-week Esomeprazole Therapy Among Los Angeles Grades A and B Erosive Esophagitis Completed NCT01874535 Phase 4 Esomeprazole 40 mg
15 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4
16 The Hannover-Dialysis-Outcome (HAN-D-OUT)-Study: Comparison of Standard Versus Intensified Extended Dialysis in Treatment of Patients With Acute Kidney Injury in the Intensive-Care Unit Completed NCT00529139 Phase 4
17 1-deamino 8-d-arginine Vasopressin in Percutaneous Ultrasound-guided Renal Biopsy: a Randomized Controlled Trial Completed NCT00748072 Phase 4 DDAVP;saline solution
18 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
19 Effects of Neutral pH and Low Glucose Degradation Product-containing Peritoneal Dialysis Fluid on Systemic Markers of Inflammation and Endothelial Dysfunction: a Randomized, Controlled 1-year Follow-up Study Completed NCT01315314 Phase 4 Balance, Fresenius Medical Care, Germany
20 Effect of Oral Vitamin C on The Inflammatory Biomarkers in Hemodialysis Completed NCT01356433 Phase 4 oral vitamin C;oral vitamin C
21 Efficacy and Safety of a Very Low Protein Diet in Postponing Dialysis in Elderly: a Prospective Randomized Multicenter Controlled Study Completed NCT00388648 Phase 4 mixture of amino and keto acids
22 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
23 Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality]) Completed NCT00124969 Phase 4 Amlodipine;Placebo
24 Effect of Replacement Volume and AST-120 (Kremezin) on Protein-bound Toxins, Oxidative Stress and MicroInflammation in Patients Receiving Online Hemodiafiltration Completed NCT01458652 Phase 4 Kremezin
25 Short-course Somatostatin Versus Terlipressin Infusion in Combination With Endoscopic Variceal Ligation for the Prevention of Early Esophageal Variceal Rebleeding Completed NCT02757703 Phase 4 Somatostatin;Terlipressin;Pantoprazole
26 A Comparison of Insulin Sensitivity and Management in Hyperglycemic Patients in the Perioperative Period: ESRD vs. Non-ESRD Recruiting NCT03526536 Phase 4 IV Novolin R human insulin
27 Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Continuous Ambulatory Peritoneal Dialysis Patients: An Open-Label Randomized-Controlled Trial Not yet recruiting NCT03953950 Phase 4 Spironolactone;Losartan
28 Circuit Survival and Efficacy for Middle Molecular-weight Solute Elimination Between Nafamostat Infusion and Heparinized Saline Priming Unknown status NCT01486485 Phase 3 heparinized saline priming group;nafamostat infusion after heparinized saline priming
29 Effects of Short-chain Fatty Acids, Here Sodium Propionate, a Metabolism Product of the Human Gut-microbiome, on Inflammatory and Metabolic Parameters in Patients on Maintenance Hemodialysis - a Pilot Study Unknown status NCT02976688 Phase 2, Phase 3
30 Effects of Convective Therapies in Dialysis Patients Completed NCT01583309 Phase 3
31 The Effect and Safety of Combination Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients Completed NCT02747979 Phase 2, Phase 3
32 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial [Glucocorticoids] Completed NCT03919825 Phase 3 Glucocorticoids - Standard Dose;Glucocorticoids - Reduced Dose
33 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial Completed NCT00987389 Phase 3 Glucocorticoids
34 Application of the Biological Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplant Completed NCT01631448 Phase 3
35 Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis (Sleep-HD) Recruiting NCT03534284 Phase 3 Trazodone;Placebo
36 Micro-elimination of Hepatitis C Virus Infection With Pan-genotypic DAA Regimen in Hepatitis C Highly Endemic and Contagious Community (ERASE-C) Recruiting NCT03891550 Phase 3 Epclusa
37 Forced Diuresis Vs Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients (Fodorefh) Terminated NCT00298454 Phase 3 Furosemide
38 Effect of Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cell in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Randomized Controlled Trial Unknown status NCT02492490 Phase 1, Phase 2 Basiliximab
39 Randomized Cross-over Trial of Oral L-Glutamine vs Maltodextrin on Mitochondrial Function in Chronic Kidney Disease Unknown status NCT02838979 Phase 2
40 The Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Multi-center Randomized Controlled Trial Unknown status NCT02561767 Phase 1, Phase 2 Induction therapy (ATG or Basiliximab);Maintenance therapy (Low-dose CNI + MPA + steroids)
41 A Prospective, Open-Label, Pilot Study of Clonal Deletion on Living-Relative Donor Kidney Transplantation Unknown status NCT01408797 Phase 1, Phase 2 MMF, Bortezomib
42 Phase 1 RCT of Progressive Resistance Training on Small Solute Clearance, Functional Capacity and Quality of Life in Intradialysis Patients Unknown status NCT01065389 Phase 2
43 Treatment of Uremic Pruritus by Olive-omega 3 Ointment Unknown status NCT01447693 Phase 1, Phase 2
44 Effect of Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cell in Living-Related Kidney Transplants: A Randomized Controlled Trial Unknown status NCT02492308 Phase 1, Phase 2 Basiliximab induction
45 A Randomised Trial of Prednisone and Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
46 Omega-3 Fatty Acid Administration in Dialysis Patients Completed NCT00655525 Phase 2
47 Clinical and Biochemical Effects of Multipass Hemodialysis Completed NCT01267760 Phase 2
48 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, CROSS-OVER STUDY TO EVALUATE THE RENAL AND BIOHUMORAL EFFECTS OF L-CYSTEINE COMPARED TO PLACEBO IN STABLE PERITONEAL DIALYSIS PATIENTS WITH RESIDUAL DIURESIS Completed NCT02050139 Phase 2
49 Vitamin D, Insulin Resistance and Inflammation in ESRD Completed NCT00656032 Phase 2
50 An Exploratory/Proof of Concept Investigation of the Safety and Pharmacodynamics of LY2127399 in HLA-Presensitized Patients With End-Stage Renal Disease Awaiting Transplantation Completed NCT01200290 Phase 2 LY2127399

Search NIH Clinical Center for Uremia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Activated Charcoal
Charcoal
CHARCOAL,ACTIVATED PWDR

Cochrane evidence based reviews: uremia

Genetic Tests for Uremia

Anatomical Context for Uremia

MalaCards organs/tissues related to Uremia:

41
Kidney, Bone, Liver, Endothelial, Testes, Brain, Heart

Publications for Uremia

Articles related to Uremia:

(show top 50) (show all 8519)
# Title Authors PMID Year
1
Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease. 9 38
20040346 2010
2
The emerging pleiotrophic role of adipokines in the uremic phenotype. 9 38
19823084 2010
3
Antioxidant properties of some different molecular weight chitosans. 9 38
19559405 2009
4
Lipoprotein lipase disturbances induced by uremia and hemodialysis. 9 38
19708998 2009
5
Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. 9 38
19212416 2009
6
Serum albumin fragmentation in end-stage renal disease patients--a pilot study. 9 38
19778290 2009
7
Antioxidant effects of a dietary supplement: reduction of indices of oxidative stress in normal subjects by water-soluble chitosan. 9 38
18996432 2009
8
Antioxidant protection of human serum albumin by chitosan. 9 38
18514811 2008
9
Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure. 9 38
18295249 2008
10
[Effects of metal-catalyzed oxidation on the formation of advanced oxidation protein products]. 9 38
18642767 2008
11
[Relationship between cardiovascular complication and inflammation, oxidative stress of patient with maintenance hemodialysis]. 9 38
18390217 2008
12
Response of the growth plate of uremic rats to human growth hormone and corticosteroids. 9 38
17665047 2007
13
Oxidative stress and delta-ALA-D activity in chronic renal failure patients. 9 38
17383846 2007
14
Alteration of serum semicarbazide-sensitive amine oxidase activity in chronic renal failure. 9 38
17431736 2007
15
Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. 9 38
17259742 2007
16
Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia. 9 38
16941045 2006
17
Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism. 9 38
16817791 2006
18
Circulating growth hormone binding protein levels and mononuclear cell growth hormone receptor expression in uremia. 9 38
16567271 2006
19
Drug-associated disease: hematologic dysfunction. 9 38
16678004 2006
20
Hyperleptinemia is not responsible for decreased paraoxonase activity in hemodialysis patients. 9 38
16534235 2006
21
Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. 9 38
16816924 2006
22
Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. 9 38
16291838 2006
23
[Inflammatoin, oxidative stress and carbonyl stress in uremic patients]. 9 38
16468659 2006
24
Oxidation and carboxy methyl lysine-modification of albumin: possible involvement in the progression of oxidative stress in hemodialysis patients. 9 38
16671336 2005
25
Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. 9 38
16047647 2005
26
Role of leptin and melanocortin signaling in uremia-associated cachexia. 9 38
15931394 2005
27
Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. 9 38
15968953 2005
28
Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. 9 38
15692835 2005
29
Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3. 9 38
15957544 2005
30
The John F. Maher Recipient Lecture 2004: Rage in the peritoneum. 9 38
15770917 2005
31
Serum paraoxonase activity in uremic predialysis and hemodialysis patients. 9 38
15593056 2004
32
Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. 9 38
14871409 2004
33
Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus. 9 38
15209435 2004
34
Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease? 9 38
14681862 2003
35
Involution of the parathyroid glands after renal transplantation. 9 38
12815332 2003
36
Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia. 9 38
12790379 2003
37
Contribution of quinolinic acid in the development of anemia in renal insufficiency. 9 38
12620922 2003
38
[Atherosclerosis and uremia: signifance of non-traditional risk factors]. 9 38
12778774 2003
39
[Renal bone disease and osteoprotegerin]. 9 38
15775096 2003
40
Impaired protein binding of Chinese medicine DanShen in uremic sera and sera with hyperbilirubinemia: rapid assessment of total and free DanShen concentrations using the fluorescence polarization immunoassay for digoxin. 9 38
12938147 2003
41
New markers of accelerated atherosclerosis in end-stage renal disease. 9 38
12649530 2003
42
Chronic liver and renal diseases differently affect structure of human serum albumin. 9 38
12485604 2002
43
The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. 9 38
12371953 2002
44
[The skeletal resistance to PTH and osteoprotegerin]. 9 38
15775364 2002
45
Novel erythropoiesis stimulating protein exerts an effect on platelet function in uremia equivalent to that exerted by recombinant human erythropoietin. 9 38
12010672 2002
46
Relationship of paraoxonase and serum lipids in Taiwan. 9 38
12149827 2002
47
[Some parameters of platelet activation in patients with uremia before and after hemodialysis (HD)]. 9 38
12731371 2002
48
Osteoprotegerin levels before and after renal transplantation. 9 38
11576949 2001
49
Carnitine metabolism in uremia. 9 38
11576925 2001
50
Metabolic consequences of hyperhomocysteinemia in uremia. 9 38
11576929 2001

Variations for Uremia

Expression for Uremia

Search GEO for disease gene expression data for Uremia.

Pathways for Uremia

GO Terms for Uremia

Cellular components related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 VWF TNFRSF11B SPP1 RETN PTH LPL
2 cell surface GO:0009986 9.77 LPL GHR EPO CASR B2M
3 endoplasmic reticulum lumen GO:0005788 9.55 SPP1 INS B2M ALB AHSG
4 extracellular space GO:0005615 9.47 TNFRSF11B SPP1 RETN PTH LPL LEP
5 platelet alpha granule lumen GO:0031093 9.43 VWF ALB AHSG
6 chylomicron GO:0042627 9.32 LPL APOC3

Biological processes related to Uremia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.88 TNFRSF11B PTH LPL B2M
2 platelet degranulation GO:0002576 9.79 VWF ALB AHSG
3 cellular calcium ion homeostasis GO:0006874 9.73 VDR PTH CASR
4 response to nutrient GO:0007584 9.71 TNFRSF11B LEP EPO
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 LEP GHR EPO
6 skeletal system development GO:0001501 9.62 VDR TNFRSF11B PTH AHSG
7 positive regulation of insulin receptor signaling pathway GO:0046628 9.61 LEP INS
8 positive regulation of glycogen biosynthetic process GO:0045725 9.6 PTH INS
9 negative regulation of lipid catabolic process GO:0050995 9.59 INS APOC3
10 high-density lipoprotein particle remodeling GO:0034375 9.58 APOC3 ALB
11 hormone metabolic process GO:0042445 9.57 LEP GHR
12 intestinal absorption GO:0050892 9.55 VDR LEP
13 negative regulation of blood vessel diameter GO:0097756 9.52 INS CRP
14 negative regulation of lipid storage GO:0010888 9.51 LEP CRP
15 chylomicron remodeling GO:0034371 9.48 LPL APOC3
16 response to fibroblast growth factor GO:0071774 9.46 PTH CASR
17 negative regulation of feeding behavior GO:2000252 9.43 RETN INS
18 regulation of cytokine production involved in inflammatory response GO:1900015 9.4 NOS2 LEP
19 interleukin-8 secretion GO:0072606 9.37 NOS2 LEP
20 cellular protein metabolic process GO:0044267 9.35 SPP1 INS B2M ALB AHSG
21 prostaglandin secretion GO:0032310 9.26 NOS2 LEP
22 interleukin-6 secretion GO:0072604 9.16 NOS2 LEP
23 acute-phase response GO:0006953 8.92 INS EPO CRP AHSG

Molecular functions related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 VWF INS GHR CRP B2M ALB
2 hormone activity GO:0005179 9.02 RETN PTH LEP INS EPO
3 peptide hormone receptor binding GO:0051428 8.96 PTH LEP

Sources for Uremia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....